Daniel Markowitz
Stock Analyst at Evercore ISI Group
(4.71)
# 139
Out of 5,090 analysts
19
Total ratings
81.25%
Success rate
22.19%
Average return
Main Sectors:
Stocks Rated by Daniel Markowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Initiates: In-Line | $68 | $65.27 | +4.18% | 1 | Nov 25, 2025 | |
| NTRA Natera | Maintains: Outperform | $190 → $250 | $242.83 | +2.95% | 2 | Nov 7, 2025 | |
| GH Guardant Health | Maintains: Outperform | $68 → $90 | $108.75 | -17.24% | 2 | Oct 30, 2025 | |
| RMBS Rambus | Maintains: Outperform | $114 → $126 | $98.48 | +27.94% | 2 | Oct 28, 2025 | |
| WST West Pharmaceutical Services | Maintains: Outperform | $350 → $390 | $281.77 | +38.41% | 3 | Oct 23, 2025 | |
| TECH Bio-Techne | Maintains: Outperform | $60 → $72 | $63.37 | +13.62% | 2 | Oct 7, 2025 | |
| RGEN Repligen | Maintains: Outperform | $155 → $175 | $165.54 | +5.72% | 4 | Oct 7, 2025 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $150 → $125 | $140.03 | -10.73% | 2 | Oct 7, 2025 | |
| TMDX TransMedics Group | Initiates: Outperform | $155 | $138.69 | +11.76% | 1 | Sep 16, 2025 |
DexCom
Nov 25, 2025
Initiates: In-Line
Price Target: $68
Current: $65.27
Upside: +4.18%
Natera
Nov 7, 2025
Maintains: Outperform
Price Target: $190 → $250
Current: $242.83
Upside: +2.95%
Guardant Health
Oct 30, 2025
Maintains: Outperform
Price Target: $68 → $90
Current: $108.75
Upside: -17.24%
Rambus
Oct 28, 2025
Maintains: Outperform
Price Target: $114 → $126
Current: $98.48
Upside: +27.94%
West Pharmaceutical Services
Oct 23, 2025
Maintains: Outperform
Price Target: $350 → $390
Current: $281.77
Upside: +38.41%
Bio-Techne
Oct 7, 2025
Maintains: Outperform
Price Target: $60 → $72
Current: $63.37
Upside: +13.62%
Repligen
Oct 7, 2025
Maintains: Outperform
Price Target: $155 → $175
Current: $165.54
Upside: +5.72%
Inspire Medical Systems
Oct 7, 2025
Maintains: Outperform
Price Target: $150 → $125
Current: $140.03
Upside: -10.73%
TransMedics Group
Sep 16, 2025
Initiates: Outperform
Price Target: $155
Current: $138.69
Upside: +11.76%